Evidence map›Paper›PMID 22567098›Full record

ArticlePloS one2012

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.

Sheila Harris, Madeleine Craze, Jillian Newton, Matthew Fisher, David T Shima, Gillian M Tozer, Chryso Kanthou

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. VEGFR1 signaling in retinal angiogenesis and microinflammation.Progress in retinal and eye research · 2021
    Review
  5. Article
  6. Review
  7. VEGFOncogene · 2019
    Article
  8. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.International journal of molecular sciences · 2018
    Review
  9. Article
  10. Article
  11. Systems Pharmacology of VEGF165b in Peripheral Artery Disease.CPT: pharmacometrics & systems pharmacology · 2017
    Article
  12. Article
  13. Article
  14. Autocrine VEGF Isoforms Differentially Regulate Endothelial Cell Behavior.Frontiers in cell and developmental biology · 2016
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sheila HarrisCancer Research United Kingdom Tumour Microcirculation Group, Department of Oncology, School of Medicine, University of Sheffield, Sheffield, United Kingdom. Sheila.harris@sheffield.ac.uk
Madeleine Craze
Jillian Newton
Matthew Fisher
David T Shima
Gillian M Tozer
Chryso Kanthou
University of Sheffield · GBSheffield Hallam University · GBUniversity College London · GB

Funding

Cancer Research UK C1276/A9993
6 · The paper itself

Abstract

Splicing of the human vascular endothelial growth factor-A (VEGF-A) gene has been reported to generate angiogenic (VEGFxxx) and anti-angiogenic (VEGFxxxb) isoforms. Corresponding VEGFxxxb isoforms have also been reported in rat and mouse. We examined VEGFxxxb expression in mouse fibrosarcoma cell lines expressing all or individual VEGF isoforms (VEGF120, 164 or 188), grown in vitro and in vivo, and compared results with those from normal mouse and human tissues. Importantly, genetic construction of VEGF164 and VEGF188 expressing fibrosarcomas, in which exon 7 is fused to the conventional exon 8, precludes VEGFxxxb splicing from occurring. Thus, these two fibrosarcoma cell lines provided endogenous negative controls. Using RT-PCR we show that primers designed to simultaneously amplify VEGFxxx and VEGFxxxb isoforms amplified only VEGFxxx variants in both species. Moreover, only VEGFxxx species were generated when mouse podocytes were treated with TGFβ-1, a reported activator of VEGFxxxb splice selection in human podocytes. A VEGF164/120 heteroduplex species was identified as a PCR artefact, specifically in mouse. VEGFxxxb isoform-specific PCR did amplify putative VEGFxxxb species in mouse and human tissues, but unexpectedly also in VEGF188 and VEGF164 fibrosarcoma cells and tumours, where splicing to produce true VEGFxxxb isoforms cannot occur. Moreover, these products were only consistently generated using reverse primers spanning more than 5 bases across the 8b/7 or 8b/5 splice junctions. Primer annealing to VEGFxxx transcripts and amplification of exon 8b primer 'tails' explained the artefactual generation of VEGFxxxb products, since the same products were generated when the PCR reactions were performed with cDNA from VEGF164/VEGF188 'knock-in' vectors used in the generation of single VEGF isoform-expressing transgenic mice from which the fibrosarcoma lines were developed. Collectively, our results highlight important pitfalls in data interpretation associated with detecting VEGFxxxb isoforms using current methods, and demonstrate that anti-angiogenic isoforms are not commonly expressed in mouse or human tissues.

Indexed as

AnimalsCell Line, TumorExonsHumansIn Vitro TechniquesMaleMiceProtein IsoformsRatsReverse Transcriptase Polymerase Chain ReactionVascular Endothelial Growth Factor AProtein IsoformsVascular Endothelial Growth Factor A

Identifiers

PMID22567098
PMCPMC3342274
OpenAlexW2053240633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.